X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
phenylthiohydantoin - analogs & derivatives (297) 297
humans (287) 287
male (271) 271
index medicus (245) 245
phenylthiohydantoin - pharmacology (210) 210
prostate cancer (172) 172
animals (153) 153
cell line, tumor (134) 134
prostatic neoplasms, castration-resistant - drug therapy (131) 131
oncology (126) 126
receptors, androgen - metabolism (126) 126
enzalutamide (121) 121
phenylthiohydantoin - therapeutic use (97) 97
androgen receptor (95) 95
receptors, androgen - genetics (87) 87
mice (84) 84
prostatic neoplasms - drug therapy (84) 84
antineoplastic agents - pharmacology (83) 83
prostatic neoplasms, castration-resistant - pathology (81) 81
prostatic neoplasms - pathology (68) 68
abiraterone (67) 67
cancer (65) 65
androgens (64) 64
prostatic neoplasms, castration-resistant - metabolism (62) 62
androgen antagonists - pharmacology (61) 61
cell proliferation - drug effects (60) 60
pharmacology & pharmacy (58) 58
drug resistance, neoplasm (57) 57
increased survival (57) 57
antineoplastic agents - therapeutic use (56) 56
chemotherapy (56) 56
article (55) 55
metastasis (55) 55
prostatic neoplasms - metabolism (55) 55
xenograft model antitumor assays (54) 54
expression (53) 53
signal transduction - drug effects (51) 51
prostate (49) 49
castration (47) 47
progression (46) 46
androgen receptor antagonists - pharmacology (45) 45
aged (44) 44
cell biology (43) 43
abiraterone acetate (40) 40
docetaxel (40) 40
mice, nude (40) 40
middle aged (40) 40
prostatic neoplasms - genetics (40) 40
prostatic neoplasms, castration-resistant - genetics (39) 39
antiandrogen (38) 38
biochemistry & molecular biology (38) 38
gene expression regulation, neoplastic - drug effects (37) 37
therapy (36) 36
care and treatment (35) 35
drug resistance, neoplasm - drug effects (34) 34
neoplasm metastasis (34) 34
antitumor-activity (32) 32
gene expression (32) 32
phenylthiohydantoin - administration & dosage (31) 31
signal transduction (31) 31
urologic and male genital diseases (31) 31
cells (30) 30
anilides - pharmacology (29) 29
apoptosis - drug effects (29) 29
mutation (29) 29
androgen antagonists - therapeutic use (28) 28
treatment outcome (28) 28
tumors (28) 28
cancer therapies (27) 27
disease progression (27) 27
endocrinology & metabolism (27) 27
resistance (27) 27
research (26) 26
aged, 80 and over (25) 25
androstenes - pharmacology (25) 25
drug therapy (25) 25
growth (25) 25
inhibition (25) 25
nitriles - pharmacology (25) 25
tosyl compounds - pharmacology (25) 25
activation (24) 24
androgen receptor antagonists - therapeutic use (24) 24
female (24) 24
mdv3100 (24) 24
urology & nephrology (24) 24
androstenes - therapeutic use (23) 23
castration-resistant prostate cancer (23) 23
drug resistance, neoplasm - genetics (22) 22
receptors, androgen - drug effects (22) 22
cell survival - drug effects (21) 21
drug synergism (21) 21
mechanisms (21) 21
pharmacology (21) 21
survival (21) 21
amino acid sequence (20) 20
analysis (20) 20
bicalutamide (20) 20
drug interactions (20) 20
gene expression regulation, neoplastic (20) 20
metastases (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 22, pp. 1665 - 1675
Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These... 
GROWTH-FACTOR RECEPTOR | CONTROLLED-TRIAL | ANTIANGIOGENIC THERAPY | ONCOLOGY | RANDOMIZED PHASE-II | BONE METASTASES | C-MET | SIPULEUCEL-T APC8015 | ABIRATERONE ACETATE | TUMOR MICROENVIRONMENT | ANGIOGENESIS INHIBITION | Cancer Vaccines - pharmacology | Humans | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Prostatic Neoplasms - immunology | RANK Ligand - pharmacology | Receptors, Androgen - drug effects | Treatment Failure | Prostatic Neoplasms - drug therapy | Phenylthiohydantoin - pharmacology | Tumor Microenvironment - drug effects | Dasatinib | Antibodies, Monoclonal - pharmacology | Angiogenesis Inhibitors - pharmacology | Clusterin - pharmacology | Pyrimidines - pharmacology | Denosumab | Prostate-Specific Antigen - blood | Orchiectomy | Signal Transduction - drug effects | Anilides - pharmacology | Mice | Receptor Cross-Talk - drug effects | Endothelin-1 - antagonists & inhibitors | Immunotherapy - methods | Taxoids - pharmacology | Ipilimumab | Tissue Extracts - pharmacology | Bone Remodeling - drug effects | Pyrrolidines - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Prostatic Neoplasms - pathology | Antineoplastic Agents, Hormonal - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Mice, SCID | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Xenograft Model Antitumor Assays | Cancer Vaccines - immunology | Pyrroles - pharmacology | Animals | RANK Ligand - antagonists & inhibitors | Pyridines - pharmacology | Thiazoles - pharmacology | Immune response | Development and progression | Cellular signal transduction | Research | Drug therapy | Health aspects | Prostate cancer | Risk factors | Review
Journal Article
Journal Article
Science, ISSN 0036-8075, 5/2009, Volume 324, Issue 5928, pp. 787 - 790
Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called... 
COS cells | Androgens | Cell lines | Agonists | Oncology | Reports | Androgen antagonists | Prostate cancer | Heterologous transplantation | Tumors | Vehicles | NONSTEROIDAL ANTIANDROGENS | STRUCTURAL BASIS | AFFINITY | MULTIDISCIPLINARY SCIENCES | ANDROGEN-RECEPTOR | RESISTANCE | ANTAGONISM | LIGAND | MODEL | BICALUTAMIDE | Transcription, Genetic - drug effects | Nitriles - pharmacology | Phenylthiohydantoin - therapeutic use | Humans | Receptors, Androgen - metabolism | Biological Availability | Male | Antineoplastic Agents - therapeutic use | Tosyl Compounds - pharmacology | Antineoplastic Agents - metabolism | Cell Nucleus - metabolism | Receptors, Androgen - chemistry | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Prostatic Neoplasms - drug therapy | Androgen Antagonists - pharmacokinetics | Phenylthiohydantoin - pharmacology | Nitriles - metabolism | Prostatic Neoplasms - pathology | Androgen Antagonists - metabolism | Androgen Antagonists - pharmacology | Anilides - metabolism | DNA - metabolism | Phenylthiohydantoin - analogs & derivatives | Xenograft Model Antitumor Assays | Animals | Receptors, Androgen - genetics | Anilides - pharmacology | Tosyl Compounds - metabolism | Androgen Antagonists - therapeutic use | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Phenylthiohydantoin - metabolism | Drug Screening Assays, Antitumor | Phenylthiohydantoin - pharmacokinetics | Care and treatment | Antiandrogens | Dosage and administration | Drug therapy | Methods | Cancer | Chemotherapy | Pharmacology | Binding sites
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 04/2016, Volume 14, Issue 4, pp. 324 - 331
Journal Article
CA Cancer Journal for Clinicians, ISSN 0007-9235, 09/2012, Volume 62, Issue 5, pp. 299 - 308
There have been more drugs approved by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer in the past 3 years than... 
GROWTH FACTOR/SCATTER FACTOR | LEUKEMIA GROUP-B | MITOXANTRONE PLUS PREDNISONE | PHASE-II TRIAL | ONCOLOGY | ORAL ESTRAMUSTINE PHOSPHATE | ABIRATERONE ACETATE | END-POINTS | RANDOMIZED CONTROLLED-TRIAL | ANTITUMOR-ACTIVITY | SIPULEUCEL-T | Castration - adverse effects | Prostate-Specific Antigen | Anilides - therapeutic use | Taxoids - pharmacology | Phenylthiohydantoin - therapeutic use | Cancer Vaccines - pharmacology | Humans | Tissue Extracts - pharmacology | Male | Antineoplastic Agents - therapeutic use | Androstenols - therapeutic use | Prostatic Neoplasms - therapy | Taxoids - therapeutic use | Cancer Vaccines - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Radiopharmaceuticals - pharmacology | Pyridines - therapeutic use | Phenylthiohydantoin - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Radium - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Tissue Extracts - therapeutic use | Denosumab | Radium - therapeutic use | Phenylthiohydantoin - analogs & derivatives | RANK Ligand - antagonists & inhibitors | Anilides - pharmacology | Pyridines - pharmacology | Radiopharmaceuticals - therapeutic use | Care and treatment | Drug therapy | Drug resistance | Laws, regulations and rules | Prostate cancer | Drug approval | Clinical trials | Chemotherapy | Castration | Pathogenesis
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2014, Volume 57, Issue 15, pp. 6458 - 6467
The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically... 
IN-VITRO | CHEMISTRY, MEDICINAL | ANTIANDROGEN | STRUCTURAL BASIS | 3 BF3 SITE | INCREASED SURVIVAL | RESISTANT PROSTATE-CANCER | CASTRATION-RESISTANT | ANTAGONISTS | SPLICE VARIANTS | ENZALUTAMIDE | Antineoplastic Agents - chemical synthesis | Humans | Molecular Conformation | Receptors, Androgen - metabolism | Imidazoles - chemistry | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Androgen Receptor Antagonists - pharmacology | Androgen Receptor Antagonists - chemistry | Computer Simulation | Transcription, Genetic | Antineoplastic Agents - pharmacology | Imidazoles - chemical synthesis | Binding Sites | Prostatic Neoplasms - drug therapy | Morpholines - chemical synthesis | Phenylthiohydantoin - pharmacology | Cell Survival - drug effects | Pyrvinium Compounds - chemistry | Prostate-Specific Antigen - secretion | Morpholines - pharmacology | Rats | Thiophenes - pharmacology | Imidazoles - pharmacology | DNA - metabolism | Antineoplastic Agents - chemistry | Morpholines - chemistry | Phenylthiohydantoin - analogs & derivatives | Thiophenes - chemical synthesis | Animals | Receptors, Androgen - genetics | Thiazoles - chemical synthesis | Databases, Chemical | Androgen Receptor Antagonists - chemical synthesis | Cell Line, Tumor | Thiazoles - chemistry | Molecular Docking Simulation | Thiazoles - pharmacology | Mutation | Thiophenes - chemistry | Pyrvinium Compounds - pharmacology | Index Medicus
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 04/2014, Volume 387, Issue 1-2, pp. 8 - 18
Journal Article
Hormones and Cancer, ISSN 1868-8497, 4/2014, Volume 5, Issue 2, pp. 72 - 89
Despite new treatments for castrate-resistant prostate cancer (CRPC), the prognosis of patients with CRPC remains bleak due to acquired resistance to androgen... 
Medicine & Public Health | Microbiology | Oncology | Internal Medicine | Systems Biology | Endocrinology | Cell Biology | SURVIVAL | APOPTOSIS | ACTIVATION | ANTIANDROGEN | ONCOLOGY | GROWTH | ENDOCRINOLOGY & METABOLISM | CASTRATION | MIFEPRISTONE | EXPRESSION | CARCINOMA | ENZALUTAMIDE | Receptors, Glucocorticoid - antagonists & inhibitors | Humans | Receptors, Androgen - metabolism | Cell Survival - genetics | Drug Resistance, Neoplasm | Immunoblotting | Male | Receptors, Glucocorticoid - metabolism | Androgen Receptor Antagonists - pharmacology | Immediate-Early Proteins - metabolism | Dexamethasone - pharmacology | Prostatic Neoplasms - genetics | RNA Interference | HEK293 Cells | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Metribolone - pharmacology | Prostatic Neoplasms - drug therapy | Protein-Serine-Threonine Kinases - metabolism | Mifepristone - administration & dosage | Phenylthiohydantoin - pharmacology | Cell Survival - drug effects | Prostatic Neoplasms - pathology | Dexamethasone - administration & dosage | Protein-Serine-Threonine Kinases - genetics | Androgen Receptor Antagonists - administration & dosage | Metribolone - administration & dosage | Reverse Transcriptase Polymerase Chain Reaction | Phenylthiohydantoin - analogs & derivatives | Xenograft Model Antitumor Assays | Phenylthiohydantoin - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Immediate-Early Proteins - genetics | Receptors, Androgen - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Receptors, Glucocorticoid - genetics | Benzoates - pharmacology | Cell Line, Tumor | Mice | Mifepristone - pharmacology | Immediate-Early Proteins - antagonists & inhibitors | Microscopy, Fluorescence | Hormone receptors | Androgens | Care and treatment | Corticosteroids | Prognosis | Prostate-specific antigen | Physiological aspects | Genetic aspects | Research | Prostate cancer
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 10/2017, Volume 15, Issue 10, pp. 1308 - 1317
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 08/2016, Volume 118, pp. 230 - 243
Prostate cancer (PC) is one of the major causes of male death worldwide and the development of new and more potent anti-PC compounds is a constant requirement.... 
Bicalutamide | Perfluoroalkyl | Enzalutamide | Antiproliferative activity | Prostate cancer | Androgen receptor | IN-VITRO | ANTIANDROGEN MONOTHERAPY | CHEMISTRY, MEDICINAL | CASTRATION-RESISTANT | Phenylthiohydantoin - chemistry | Phenylthiohydantoin - chemical synthesis | Nitriles - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Microsomes, Liver - metabolism | Receptors, Androgen - metabolism | Anilides - chemistry | Male | Nitriles - chemical synthesis | Anilides - chemical synthesis | Tosyl Compounds - pharmacology | Antineoplastic Agents - metabolism | Tosyl Compounds - chemical synthesis | Drug Design | Receptors, Androgen - chemistry | Antineoplastic Agents - pharmacology | Caco-2 Cells | Phenylthiohydantoin - pharmacology | Nitriles - metabolism | Prostatic Neoplasms - pathology | Chemistry Techniques, Synthetic | Anilides - metabolism | Tosyl Compounds - chemistry | Permeability | Antineoplastic Agents - chemistry | Molecular Dynamics Simulation | Phenylthiohydantoin - analogs & derivatives | Anilides - pharmacology | Nitriles - chemistry | Tosyl Compounds - metabolism | Cell Line, Tumor | Protein Conformation | Cell Proliferation - drug effects | Molecular Docking Simulation | Phenylthiohydantoin - metabolism | Drug Resistance, Neoplasm - drug effects | Care and treatment | Drug therapy | Drug approval | Analysis | Cancer
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 07/2013, Volume 288, Issue 27, pp. 19359 - 19369
Journal Article
Oncotarget, ISSN 1949-2553, 2015, Volume 6, Issue 30, pp. 29782 - 29794
Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR... 
FOXA1 | Androgen receptor variants | Transcriptional regulation | Prostate cancer | RECRUITMENT | androgen receptor variants | EVENTS | transcriptional regulation | SPLICE VARIANTS | CELL BIOLOGY | prostate cancer | THERAPY | INCREASED SURVIVAL | ENZALUTAMIDE RESISTANCE | EXPRESSION | BINDING | ABIRATERONE | Nitriles - pharmacology | Humans | Receptors, Androgen - metabolism | Male | Gene Expression Profiling | Prostatic Neoplasms, Castration-Resistant - genetics | Prostatic Neoplasms, Castration-Resistant - pathology | Tosyl Compounds - pharmacology | RNA Interference | Dihydrotestosterone - pharmacology | Antineoplastic Agents - pharmacology | Prostate-Specific Antigen - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Gene Expression Regulation, Neoplastic - genetics | Phenylthiohydantoin - pharmacology | Prostate-Specific Antigen - genetics | Cell Proliferation - genetics | Kallikreins - genetics | Androgen Antagonists - pharmacology | Hepatocyte Nuclear Factor 3-alpha - genetics | Reverse Transcriptase Polymerase Chain Reaction | Prostatic Neoplasms, Castration-Resistant - metabolism | Blotting, Western | Phenylthiohydantoin - analogs & derivatives | Hepatocyte Nuclear Factor 3-alpha - metabolism | Receptors, Androgen - genetics | Androgens - pharmacology | Anilides - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mutation | Kallikreins - metabolism
Journal Article